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We present the uncommon case of a subcutaneous fascia-based extramedullary plasmacytoma in the leg, which was conﬁrmed by
the pathology report and followed up until its remission. We report the diﬀerential diagnosis with other more common soft tissue
masses. Imaging ﬁndings are nonspeciﬁc but are important to determine the tumour extension and to plan the biopsy.
1.Introduction
Extramedullary plasmacytoma (EMP) accounts for 3% of
myeloma cases and is usually localized in submucosal
lymphoidtissueofnasopharyngealandparanasalsinuses[1].
Soft tissue localization elsewhere is extremely uncommon,
andothermorecommontypesofsofttissuemassareinitially
suspected. We present a case of soft tissue plasmacytoma in
the leg, conﬁrmed by the pathology report and followed up
until its remission.
2.CaseReport
A 52-year-old male was referred to the orthopaedic surgeon
for evaluation of a painless bulge in his calf detected 1
year earlier. An MRI was performed in a Signa 1.5 T GE,
obtaining axial and sagittal T1- (FSE, TE: 25; TR: 540, ETL:
4)andT2∗-(GE,TE:15;TR:620ms,ﬂipangle:20)weighted
images. A homogeneous, oblong and well-deﬁned mass was
detected superﬁcial to the Achilles tendon. It was isointense
on T1-weighted images and hyperintense on T2∗-weighted
images and showed homogeneous moderate enhancement
after intravenous gadolinium injection (Figure 1).
A Tru-Cut biopsy was performed, and the pathology
report described a neoplastic proliferation of diﬀerentiated
plasma cells. Immunochemistry studies showed cells to be
positivetoCD138(plasmacellmarker)andnegativetoCD20
(accompanying B-lymphocytes) and CD3 (accompanying
T-lymphocytes). These ﬁndings supported the diagnosis
of plasmacytoma (Figure 2). The presence of any other
abnormality was ruled out by subsequent haematological
study (bone marrow biopsy, complete blood count and
electrophoresis) and PET-CT examination.
The patient was treated by radiotherapy. A very small
residual ﬂat thickening of soft tissues, which shows no
activity on PET-CT, remains unchanged after four years
of followup. The patient is considered to be in complete
remission.
3. Discussion
Myeloma usually appears as a generalized disease (multiple
myeloma). In a small proportion of patients (<5%), it can
present as solitary bone plasmacytoma (SBP) or a solitary
soft tissue mass, extramedullary plasmacytoma (EMP) [2].
Primary plasmacytoma, whether osseous or nonosseous,
is distinguished from multiple myeloma by absence of
hypercalcaemia, renal insuﬃciency and anaemia, normal
skeletal survey, absence of bone marrow plasmacytosis, and
serum or urinary paraprotein <2g/dL[3].2 Case Reports in Medicine
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Figure 1: Sagittal T1 (a), T2∗ (b) weighted images depict a fusiform mass over the Achilles tendon. Postcontrast sagittal T1 (c) and axial
fat-saturated T1-weighted images demonstrate a moderate and homogeneous enhancement.
The diagnosis of EMP requires demonstration of a mon-
oclonal plasma cell inﬁltrate with no evidence of myeloma
at any other site. Therefore, patients with presumed soli-
tary plasmacytoma of bone or soft tissue (extramedullary)
plasmacytoma should undergo a radiological bone survey
and MR imaging to ensure that only one lesion is present.
Imaging studies should focus on the early detection of
additional or recurrent lesions and the presence of regional
lymphadenopathy, which will inﬂuence the clinical manage-
ment.
Solitary plamocytomas can arise at any site, but almost
90% develop in the head and neck area and especially in the
upper respiratory tract (nose, paranasal sinuses, nasophar-
ynx and tonsils). Infrequent sites of involvement include the
gastrointestinal tract, liver, spleen, pancreas, lungs, thyroid,
breast, testis or skin [4, 5]. Solitary plasmacytoma presenting
as a soft tissue mass is therefore a rare event and not usually
included in the diﬀerential diagnosis of other more common
soft tissue masses, such as sarcomas, ﬁbrous tumours,
haemangiomas, neuroﬁbromas or lymphomas.
Malignant ﬁbrous histiocytoma is the most frequent
mesenchymal malignancy and accounts for around 24% of
all soft-tissue sarcomas, with 7–10% of cases conﬁned to the
subcutaneous tissue, where it may or not extend to the fascia.
Subcutaneous lesions tend to be smaller, implying a better
CD138 CD20 CD3
Figure 2: Neoplastic proliferation of diﬀerentiated plasma cells.
Immunochemistry was positive for CD138 (plasma cell marker)
and negative for CD20 (accompanying B-lymphocytes) and CD3
(accompanying T-lymphocytes).
prognosis. MR imaging of soft-tissue malignant ﬁbrous
histiocytomas reveals lesions with intermediate to low signal
intensity on T1-weighted images and inhomogeneous high
signal intensity on T2-weighted images. Inhomogeneity
may be due to calciﬁcation, myxoid degeneration withCase Reports in Medicine 3
cystic cavities or necrosis. After gadolinium administra-
tion, irregular enhancement is seen in the viable tumour
[6].
Synovial sarcomas account for around 10% of all soft-
tissue sarcomas. The MR signal is usually complex, due
to the presence of ﬂuid levels, haemorrhage and internal
septation. Neoplasms with a diameter <5cm may have a
more benign appearance, with well-circumscribed margins
and homogeneous high signal intensity on T2-weighted
images [6].
Among ﬁbrous tumours, nodular fasciitis can present
as a localized and circumscribed subcutaneous fascia-based
mass. The histologic diversity of nodular fasciitis likely
accounts for the variable MR appearance of the lesions. In
hypercellular lesions, they can appear isointense to slightly
hyperintense relative to skeletal muscle on T1-weighted
images and hyperintense to adipose tissue on T2-weighted
images.Highlycollagenouslesionsshowahypointensesignal
on all MR images. Contrast enhancement is typically diﬀuse
and homogeneous, except in cases of myxoid degeneration
leading to cystic degeneration [7].
Soft-tissue haemangiomas can arise at various anatomic
sites, including striated muscle, skin, subcutaneous tissue
and synovial tissue, depending on the histologic subtype. If
suﬃciently large, they can manifest as a smooth, palpable
soft-tissue mass. MR imaging reﬂects the mix of tissues
present in the haemangioma. It usually shows heterogeneity,
due to the variable amount of fat, arteries and veins, which
can present a serpentine pattern. Nevertheless, small lesions
with no fat content can have a homogeneous signal and well-
deﬁned border [8].
Subcutaneous neuroﬁbromas are usually associated with
neuroﬁbromatosis-1. An entering and exiting nerve cannot
usually be identiﬁed in superﬁcial lesions. They generally
present as a fusiform-shaped mass with a signal that is
isointense to skeletal muscle on T1-weighted MR images and
hyperintense to skeletal muscle on T2-weighted images, with
variable degrees of inhomogeneity and enhancement [8].
Musculoskeletal involvement by lymphoma can occur
in disseminated disease or as an isolated manifestation
(primary lymphoma of bone, muscle, cutaneous or sub-
cutaneous tissue). The skin is the second most common
site of extranodal involvement of Non-Hodgkin Lymphoma
after the gastrointestinal tract. Imaging features of cutaneous
lymphomaarenonspeciﬁcandincludesofttissuethickening,
inﬁltration or a mass [9].
Most of the above diagnoses have to be considered before
soft tissue EMP is diagnosed. Although EMP ﬁndings are
not speciﬁc, imaging can be used to delineate the extent
of the mass, plan a biopsy and rule out other lesions.
In MRI studies, it has been described as a mass that is
isointense or slightly hyperintense on T1-weighted images
and isointense to high hyperintense on T2-weighted images,
withhomogeneous-to-heterogeneousenhancementonpost-
contrast T1-weighted images [1, 10]. Its appearance is
inﬂuenced by its size, with small lesions visualized as well
deﬁned and homogeneous, while larger lesions tend to be
invasive and heterogeneous due to the development of areas
of necrosis.
The prognosis is signiﬁcantly better for EMP patients
than for SBP patients, with two-thirds surviving >10 years
[11], and currently available radiotherapy techniques have
minimized the likelihood of local recurrence [12]. The risk
of distant metastasis or conversion to multiple myeloma, is
<30%. Distant metastases tend to appear within 2-3 years
of the initial diagnosis, and a close follow-up is warranted
during this period [13].
In summary, we present a rare case of subcutaneous
fascia-based EMP, reporting the diﬀerential diagnosis with
other more common soft tissues mass. Imaging ﬁndings are
nonspeciﬁc but invaluable for studying the extent of the
tumour and planning the biopsy.
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